Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6959201 | 1.00 | AGTR1 (0.75) | AGTR1 | |
| SCHEMBL9424090 | 0.94 | — | — | |
| SCHEMBL9424094 | 0.94 | — | — | |
| SCHEMBL10442005 | 0.91 | — | — | |
| SCHEMBL10442003 | 0.91 | — | — | |
| SCHEMBL9489974 | 0.91 | — | — | |
| SCHEMBL9424164 | 0.90 | — | — | |
| SCHEMBL9424158 | 0.90 | — | — | |
| SCHEMBL9424389 | 0.89 | — | — | |
| SCHEMBL9424382 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0955294-A2 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-10 | — | — | EP | claimed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | claimed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | claimed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | BRAINCELLS INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-0955294-B1 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORP (US) | 2003-09-24 | — | — | EP | disclosed |
| EP-0955294-A2 | Imidazolyl-alkenoic acid | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-10 | — | — | EP | disclosed |
| US-5418250-A | Hypotensive | SMITHKLINE BEECHAM CORPORATION (US) | 1995-05-23 | — | — | US | disclosed |
| EP-0641203-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1995-03-08 | — | — | EP | disclosed |
| EP-0641203-A4 | IMIDAZOLYL-ALKENOIC ACIDS. | SMITHKLINE BEECHAM CORP (US) | 1994-06-09 | — | — | EP | disclosed |
| EP-0425211-B1 | Substituted 5-((tetrazolyl)alkenyl)-imidazoles | SMITHKLINE BEECHAM CORP (US) | 1994-03-30 | — | — | EP | disclosed |
| WO-1993003722-A1 | IMIDAZOLYL-ALKENOIC ACIDS | SMITHKLINE BEECHAM CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
| US-5185351-A | Hypotensive agents; for treatment of congestive heart failure, renal failure and glaucoma | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-09 | — | — | US | disclosed |
| US-5177096-A | Angiotensin II receptor antagonist | SMITHKLINE BEECHAM CORPORATION (US) | 1993-01-05 | — | — | US | disclosed |
| EP-0425211-A1 | Substituted 5-((tetrazolyl)alkenyl)-imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-05-02 | — | — | EP | disclosed |
| EP-0403159-A2 | Imidazolyl-alkenoic acids | SMITHKLINE BEECHAM CORPORATION (US) | 1990-12-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046090-A1 | MODULATION OF NEUROGENESIS WITH GABA AGENTS AND GABA ANALOGS | GAP43, GABRB1, GABRB3 | AGTR1 3252/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | AGTR1 8/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.